Medpace Holdings Inc(MEDP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | 34.46 | EPS (ttm) | 17.05 | Insider Own | 19.48% | Shs Outstand | 27.8M | Perf Week | -0.99% |
| Market Cap | 16.40B | Forward P/E | 30.36 | EPS next Y | 9.92% | Insider Trans | -3.26% | Shs Float | 22.5M | Perf Month | -1.58% |
| Enterprise Value | 16.04B | PEG | 2.52 | EPS next Q | 4.41 | Inst Own | 89.66% | Short Float | 7.44% | Perf Quarter | 23.67% |
| Income | 0.49B | P/S | 5.89 | EPS this Y | 15.2% | Inst Trans | 1.97% | Short Ratio | 5.64 | Perf Half Y | 32.37% |
| Sales | 2.78B | P/B | 37.7 | EPS next 5Y | 12.05% | ROA | 27.09% | Short Interest | 1.67M | Perf YTD | 4.61% |
| Book/sh | 15.58 | P/C | 32.62 | EPS past 3/5Y | 28.02% 31.79% | ROE | 162.15% | 52W High | -13.33% ($677.90) | Perf Year | 18.07% |
| Cash/sh | 18.01 | P/FCF | 23.2 | Sales past 3/5Y | 20.12% 22.27% | ROIC | 88.72% | 52W Low | 57.51% ($373.00) | Perf 3Y | 110.32% |
| Dividend Est. | - | EV/EBITDA | 26.24 | EPS Y/Y TTM | 25.88% | Gross Margin | 27.76% | Volatility(W/M) | 1.92% 2.65% | Perf 5Y | 206.46% |
| Dividend TTM | - | EV/Sales | 5.77 | Sales Y/Y TTM | 24.67% | Oper. Margin | 20.97% | ATR (14) | 15.71 | Perf 10Y | 1888.22% |
| Dividend Ex-Date | - | Quick Ratio | 0.73 | EPS Q/Q | 37.23% | Profit Margin | 17.67% | RSI (14) | 48.94 | Recom | 2.93 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.73 | Sales Q/Q | 17.24% | SMA20 | -1.88% ($598.78) | Beta | 1.19 | Target Price | $601.09 |
| Payout | - | Debt/Eq | 0.33 | Earnings | 2026/7/22 | SMA50 | 1.59% ($578.32) | Rel Volume | 0.53 | Prev Close | $583.16 |
| Employees | 6200 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | 6.84% 2.58% | SMA200 | 12.83% ($520.71) | Avg Volume(3M) | 0.30M | Price | $587.52 |
| IPO | 2016/8/11 | Option/Short | Yes/Yes | Trades | 7835 | Volume | 158,324 | Change | 0.75% |
Company
MEDP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. contract research organization (CRO) that provides full-service, end-to-end clinical trial services—including the design, execution, and management of clinical studies—on behalf of pharmaceutical and biotech companies. The firm specializes in conducting clinical trials as an outsourced partner and primarily serves small- and mid-cap biotech companies.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
MEDP makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +15.2% this year.
Tap to view numbers
The price looks about right
Trading at 34.5 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by +110.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 89.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
KNOW 0.03%
BOUT 0.03%
ALIL 0.03%
MCOW 0.03%
AMID 0.03%It ranks #4 in the industry
Based on market cap of $16B.
MEDP $16B PER 34.5
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is MEDP?
MEDP belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of MEDP?
The market cap of MEDP is approximately $16.4B, ranking 686 within its sector.
What is the P/E ratio of MEDP?
MEDP has a P/E ratio of approximately 34.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MEDP?
MEDP has recorded a 52-week high of $677.90 and a low of $373.00.
